2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …

E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …

N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the …

K Zeppenfeld, J Tfelt-Hansen, M De Riva… - European heart …, 2022 - academic.oup.com
4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization …

M Glikson, JC Nielsen, MB Kronborg, Y Michowitz… - EP …, 2022 - academic.oup.com
for digital applications (smartphones, etc.). These versions are abridged and thus, for more
detailed information, the user should always access to the full text version of the guidelines …

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

TA McDonagh, M Metra, M Adamo… - European heart …, 2021 - academic.oup.com
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action

E Marijon, K Narayanan, K Smith, S Barra, C Basso… - The Lancet, 2023 - thelancet.com
Despite major advancements in cardiovascular medicine, sudden cardiac death (SCD)
continues to be an enormous medical and societal challenge, claiming millions of lives …

[HTML][HTML] Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020

ДС Лебедев, ЕН Михайлов… - Российский …, 2021 - cyberleninka.ru
Члены Рабочей группы подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Рабочей …

Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches

S Heymans, NK Lakdawala, C Tschöpe, K Klingel - The Lancet, 2023 - thelancet.com
Dilated cardiomyopathy is conventionally defined as the presence of left ventricular or
biventricular dilatation or systolic dysfunction in the absence of abnormal loading conditions …

A research agenda for ageing in China in the 21st century: Focusing on basic and translational research, long-term care, policy and social networks

EF Fang, C **e, JA Schenkel, C Wu, Q Long… - Ageing research …, 2020 - Elsevier
One of the key issues facing public healthcare is the global trend of an increasingly ageing
society which continues to present policy makers and caregivers with formidable healthcare …